Publications by authors named "Yael Gelfend"
Anticancer Res
November 2022
Article Synopsis
- Tumor cell lines play a key role in studying cancer biology and responses to treatment, specifically focusing on how BRCA1/2 mutations impact sensitivity to the PARP inhibitor talazoparib.
- Researchers analyzed various BRCA1/2-mutant cell lines from human breast and ovarian cancer specimens to assess their growth response after treatment with talazoparib.
- The results showed a partial link between specific BRCA mutations and sensitivity to the drug, with some cell lines being sensitive while others, even with similar mutations, showed resistance, suggesting that loss of heterozygosity (LOH) may not always predict treatment efficacy.
